On the other hand, emerging evidence reveals that GPNMB+TAMs in melanoma and breast cancer microenvironments exhibit significant upregulation of immunosuppressive markers including TREM2 and CD206 (Liu et al., 2024). This evidence concerns the gene GPNMB and breast carcinoma.